Next Article in Journal
A Class I HDAC Inhibitor BG45 Alleviates Cognitive Impairment through the CaMKII/ITPKA/Ca2+ Signaling Pathway
Next Article in Special Issue
Antiviral Effect of Stenocline ericoides DC. and Stenocline inuloides DC., Two Flavonoid-Rich Endemic Plants from Madagascar, against Dengue and Zika Viruses
Previous Article in Journal
Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties
Previous Article in Special Issue
Novel Aporphine- and Proaporphine–Clerodane Hybrids Identified from the Barks of Taiwanese Polyalthia longifolia (Sonn.) Thwaites var. pendula with Strong Anti-DENV2 Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 12
10.3390/ph15121480
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones

by
Ryosuke Morimoto
1,†,
Chiaki Matsubara
1,
Akari Hanada
1,
Yuta Omoe
2,
Tokutaro Ogata
2 and
Yuji Isegawa
1,*
1
Department of Food Sciences and Nutrition, Mukogawa Women’s University, Nishinomiya 663-8558, Hyogo, Japan
2
Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, 920-1181, Ishikawa, Japan
*
Author to whom correspondence should be addressed.
†
Present address: Faculty of Human Life Science, Shikoku University, Tokushima 771-1192, Tokushima, Japan.
Pharmaceuticals 2022, 15(12), 1480; https://doi.org/10.3390/ph15121480
Submission received: 5 October 2022 / Revised: 21 November 2022 / Accepted: 22 November 2022 / Published: 28 November 2022
(This article belongs to the Special Issue Antiviral Compounds in Medicinal Plants)
Browse Figures
Versions Notes

Abstract

:
Vaccines and antiviral drugs are widely used to treat influenza infection. However, they cannot rapidly respond to drug-resistant viruses. Therefore, new anti-influenza virus strategies are required. Naringenin is a flavonoid with potential for new antiviral strategies. In this study, we evaluated the antiviral effects of naringenin derivatives and examined the relationship between their cellular uptake and antiviral effects. Madin–Darby canine kidney (MDCK) cells were infected with the A/PR/8/34 strain and exposed to the compound-containing medium for 24 h. The amount of virus in the supernatant was calculated using focus-forming reduction assay. Antiviral activity was evaluated using IC50 and CC50 values. Cells were exposed to a constant concentration of naringenin or prenylated naringenin, and intracellular uptake and distribution were evaluated using a fluorescence microscope. Prenylated naringenin showed strong anti-influenza virus effects, and the amount of intracellular uptake was revealed by the strong intracellular fluorescence. In addition, intracellular distribution differed depending on the position of the prenyl group. The steric factor of naringenin is deeply involved in influenza A virus activity, and prenyl groups are desirable. Furthermore, the prenyl group affects cellular affinity, and the uptake mechanism differs depending on its position. These results provide important information on antiviral strategies.

Graphical Abstract

1. Introduction

The influenza virus is an RNA virus that belongs to the family Orthomicroviridae, which mainly causes infections in mammals. While the spread of COVID-19 appears to have reduced influenza virus infections [1], co-infections in animals [2] and humans [3] have been reported. Influenza virus has caused pandemics, with many reported deaths [4,5]. Due to its susceptibility to antigenic variation [6], influenza virus may cause a pandemic in the future.
Several agents have been developed for the treatment of influenza. M2 channel blockers (amantadine and rimantadine), neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, and laninamivir), viral RNA polymerase inhibitor (favipiravir), and cap-dependent endonuclease inhibitor (baloxavir marboxil) are known. Antiviral drugs, such as oseltamivir, act directly on the virus multiplication mechanism. However, successive reports of drug-resistant strains or potential have been reported [7,8]. Lampejo warned that new antiviral strategies should be con-sidered when preparing for a pandemic [9].
Natural plant compounds are important sources for future drug development. Flavonoids are plant secondary metabolites classified as polyphenols. Naringenin is classified as a flavanone and is present in plants such as citrus fruits and others [10,11,12]. Flavanone group compounds and derivatives have broad-spectrum biological activity [13,14,15,16,17,18] and have attracted attention as antiviral agents [19]. Recently, the physiological functions, including biological and pharmacological effects of prenylated compounds have been reported [19,20,21,22,23,24]. We previously reported that 8-prenylnaringenin (8-PN) isolated from wild watermelon (Citrullus lanatus var. citroides (L.H. Bailey)) exhibits high antiviral activity [25]. Therefore, we believe that plants rich in prenylated compounds have the potential to be important sources for antiviral drug development strategies. For example, xanthohumol, 8-PN, and 6-prenylnaringenin (6-PN), which are produced by hop (Humulus lupulus L.) [26,27].
Additionally, we reported that the antiviral activity of flavonoids depends on the type and structure of the modifying group, suggesting that this may be due to the differences in substituent position, steric effect, and coordination effect of the compound [28]. When considering anti-influenza virus strategies, it is important to study the effects of these chemical structures and the pharmacokinetics of tissues and cells. Mukai et al. reported the cellular uptake of flavonols, quercetin, and 8-prenyl quercetin [29]. However, the cellular distribution of prenylated naringenin has not been fully investigated. Therefore, in this paper, to investigate the chemical and pharmacological properties related to antiviral activity, derivatives with several substituents with different properties were synthesized to elucidate the relationship between the cellular uptake and intracellular distribution of prenylated naringenin and its antiviral activity.

2. Results

To investigate the viral effects of chemical structure, we synthesized compounds based on 8-PN and 6-PN. The chemical structures of the compounds were confirmed using 1H NMR (500 MHz) and 13C NMR (125 MHz). The synthesized compound information is shown in Figures S1–S32 and Supplementary Materials. This was within the range of no cytotoxicity.

2.1. Anti-Influenza Activity of Prenylated Naringenin (8-PN, 6-PN) and Other Derivatives (1a–2d)

First, we evaluated four compounds (naringenin, naringenin-4′,7′-diacetate, 8-PN, and 6-PN). The IC50 value of naringenin was 290 μM. Additionally, naringenin-4′,7-diacetate markedly lost its anti-influenza activity. Prenylated naringenin, 8-PN and 6-PN, showed strong activity with IC50 values of 24 and 38 μM, respectively. Compared to naringenin, prenylation of the 8- or 6-position dramatically increases anti-influenza virus activity. However, no significant difference in activity was observed between the 8- and 6-position substituents (Table 1).

2.2. Coordination Effect of Modifying Groups on the Naringenin Skeleton 8-Position

Next, we evaluated the effect of unshared electron pairs 1a, 1b, and 1e. Compound 1a, in which an epoxide group was introduced into the molecular structure, showed activity at 59 μM, but was less active than 8-PN (Table 1). The activities of 1b and 1e were lost. In addition, to evaluate the coordination ability of the double bonds in the molecular structure at the 8-position, additional compounds were synthesized. The IC50 values of compounds 1c and 1d, which are saturated hydrocarbon side chains, were 42 and 61 μM, respectively.

2.3. Stereoscopic Effect of Modifying Groups on the Naringenin Skeleton

Previous studies have also suggested the effect of steric factors on the anti-influenza virus effect [28]. Subsequently, to investigate the steric effect, substituents with different steric effects (allyl groups: 2a, isopentyl group: 2b, cycloalkanes: 2c and 2d) were introduced. Compounds 2a and 2b showed weaker activities than 6-PN. The activities of 2c and 2d were not detected. In addition, isopentyl derivatives (1d and 2b), showed lower activity than prenylated naringenins (Table 1).

2.4. Uptake of Naringenin and Prenylated Naringenin into Madin–Darby Canine Kidney (MDCK) Cells

From the obtained results (Table 1), it was found that the substituents in the flavanone skeleton greatly affected antiviral activity. To confirm the relationship between compound uptake and antiviral activity, we evaluated intracellular uptake by fluorescence microscopy. The experiment was conducted by modifying the method described by Wolf et al. [30]. Figure 1, Figure 2 and Figure 3 summarize the fluorescence intensity of each compound per 20 cells at each time point. This fluorescence intensity transition was also confirmed by the images. Images obtained after 180 min are shown in Figure 1B, Figure 2B and Figure 3B. Several compounds increased the fluorescence intensity after 120 min, reaching plateaus between 180 and 360 min. Naringenin, naringenin-4′,7′-diacetate, 8-position derivatives, and 6-position derivatives showed low fluorescence intensity, whereas 8-PN and 6-PN showed high fluorescence intensity (Figure 1A, Figure 2A and Figure 3A). This fluorescence intensity transition was also confirmed by the images (Figure 1B, Figure 2B and Figure 3B). In addition, the isopentyl group (1d) showed stronger fluorescence intensity than the other compounds. The fluorescence intensity at 360 min decreased in the order of 8-PN > 6-PN > 1d > other compounds.

2.5. Intracellular Distribution of Naringenin and Prenylated Naringenin

Based on these results, we investigated the intracellular distributions of naringenin and prenylated naringenin. Cells cultured on glass plates were exposed to a concentration of 30 μM for 180 min. The exposed cells were washed with PBS and the compounds were removed from the medium. The cells were then fixed with 4% paraformaldehyde and observed under a fluorescence microscope. At 30 μM, the intracellular prenylated naringenin group showed a remarkable fluorescence pattern (Figure 4). The amount of naringenin taken up by the cells may be small. Moreover, fluorescence was detected for prenylated naringenin. We confirmed that 8-PN was distributed mostly in the cytoplasm and nucleus, while 6-PN tended to localize to the cytoplasmic periphery.

2.6. Extracellular Kinetics of Prenylated Naringenin

Based on our results, we examined the kinetics of intracellular prenylated naringenin in Dulbecco’s Modified Eagle Medium (DMEM) containing 1% fetal bovine serum (FBS). After 180 min of exposure, the cells were cultured in compound-free medium and fluorescence was observed at each time point. Consequently, each prenylated naringenin exhibited different kinetics. Intracellular 8-PN was released from the cell slowly, while 6-PN was released relatively quickly (Figure 5 and Figure 6). The intracellular kinetics changed greatly depending on the position of the prenyl group. After 120 min of culturing in the medium, the fluorescence intensity of 8-PN and 6-PN increased approximately 1.6-fold and 9.4-fold, respectively, compared to that at 0 min (Figure 6).

2.7. Growth of Influenza Virus Was Inhibited by Prenylated Naringenin

We performed a time-of-addition assay to verify the effect of the prenyl group position on viral growth inhibition. Figure 7A,B show virus viability when exposed to each prenylated naringenin for each time duration. It was commonly inhibited after infection at the late stage (4–8 h, 6–8 h). However, 8-PN and 6-PN showed characteristic inhibition, depending on the position of the prenyl group. When exposed to prenylated naringenin during the virus adsorption period (−1–0 h), 8-PN was confirmed to have a high inhibitory effect. Conversely, 6-PN showed a high inhibition tendency during a 2 h exposure time (4–6 h). In previous studies, inhibitory effects differed depending on the flavonoid backbone [28]. The anti-influenza virus effect depends on the position of the prenyl group, which is a novel observation of the present study.

3. Discussion

The antiviral effects of some flavonoid aglycones and their derivatives have been investigated [31,32] and have the potential to inhibit each viral growth stage [33,34,35]. Naringenin has been reported to be effective against various viruses [36,37], but there are few reports on its effectiveness against influenza viruses. We have previously reported the antiviral effects of 8-PN in plants [25]; 8-PN showed stronger activity than naringenin. In addition, we reported that the antiviral effect depends on the structure of the flavonoids [28]. Here, we investigated the anti-influenza effects of naringenin derivatives and their kinetics in cells.
First, we focused on the relationship between the structure and activity of naringenin and its derivatives, including prenylated naringenin. We hypothesized that the structure of the substituents was a factor in viral activity and synthesized 13 compounds with substituents with different properties. Naringenin showed antiviral activity, while naringenin-4′,7′-diacetate lost its activity. We predicted that the diacetyl structure is involved in the expression of activity. However, compound 1c exhibited antiviral activity at 42 μM. These results suggest that the 8-position substituent, rather than the 4′and 7′ positions, is essential for anti-influenza virus activity. Additionally, the activity was expressed by the isopentyl group (1c and 1d); however, 1b and 1e were not active. These results suggested that the dimethyl structure of the carbon chain is involved in the expression of activity. The epoxide group (1a) had decreased anti-influenza virus activity. Therefore, substituents (hydrocarbon chains) that do not exhibit coordinating properties in the flavanone skeleton are desirable.
Next, the antiviral activities of the 6-position derivatives were evaluated. Since the activity of 6-allylnaringenin (2a) decreased, highlighting the effect of the length of the carbon chain rather than the electronic effect of the substituents, it was inferred that a steric factor was also involved in the 6-position derivatives. The effect of the double-bond site in the substituent is thought to be due to the coordinating property or partial planarity, but no clear factor could be confirmed. However, unsaturated substituents would be desirable, as compounds with double bonds show stronger activity (Table 1). In addition, the 2c and 2d results suggest that cyclohexane may be a steric obstacle for activity, and the steric size suitable for the anti-influenza virus effect was the dimethyl structure in the prenyl group, which has a branched structure.
Therefore, 8-PN and 6-PN showed the strongest activities among the synthesized derivatives group, and the prenyl group dramatically affected the anti-influenza virus effect. The results of the 8- and 6-position derivatives suggest that the steric factors of the compounds are deeply involved in anti-influenza virus activity.
In addition, based on the research report by Murota et al. [38], we speculated that the prenyl group has the potential to enhance affinity with cell lipid membranes and increase cellular uptake. To confirm this hypothesis, we exposed cultured cells to naringenin and prenylated naringenin and observed them using fluorescence microscopy. Cellular uptake experiments confirmed the characteristic fluorescence intensity depending on the structure of the compound (Figure 1, Figure 2 and Figure 3). After 180 min of exposure, many compounds showed a plateau in MDCK cells, and 1d, 8-PN, and 6-PN showed high fluorescence intensities in each derivative group. These results indicate that the prenyl and isopentyl groups at the 8-position enhance the affinity to cells and to the cell membrane or other uptake factors. When further cellular distribution was examined by fluorescence microscopy and compared to naringenin, the distribution of fluorescence was clearly confirmed (Figure 4). Tanaka et al. reported that the cellular uptake of 8-PN in HEK293 cells was higher than that of naringenin [39], and similar results were obtained in MDCK cells. While 8-PN was localized throughout the nucleus and cytoplasm, 6-PN was localized in the periphery of the cytoplasm. This kinetics can be attributed to the in vivo interactions of each compound. Low-molecular-weight compounds such as flavonoids are known to bind to proteins in vivo, and albumin is also used as an indicator of in vivo nutrition [40]. Flavonoids have also been reported to have a high affinity for intracellular proteins [41,42], which is not only due to the affinity of the compound to the cell membrane, but also due to the interaction with intracellular proteins. The fact that the medium contained approximately 20 nM albumin during fluorescence microscopy and about 60 μM at the time of the addition assay may also affect the results. To confirm the kinetics of prenylated naringenin, we prepared cells saturated with the compound. After saturation, the cells were exposed to DMEM containing 1% FBS and fluorescence was observed at each time point. Consequently, the intracellular amount of 8-PN decreased slowly, and that of 6-PN decreased dramatically (Figure 5 and Figure 6). These results indicate that the intracellular residence time of prenylated flavonoids increased and affected the efflux time. Mukai et al. reported the intracellular localization of flavonols and flavones in fluorescence microscopy experiments; their behaviors differed depending on the substituent [43]. To clarify the anti-influenza virus mechanism of each flavonoid, it is necessary to investigate the intracellular uptake mechanisms, such as endocytosis, passive diffusion, and membrane transporters, in detail. The kinetics of this prenylated compound are of great interest and provide pharmacological insights into antiviral strategies.
This result suggests different intracellular kinetics, which may also be involved in the antiviral effects. Although 8-PN and 6-PN commonly block the late stage of viral growth (6–8 h), a time-of-addition assay revealed that the inhibitory effect on the antiviral effect differs depending on the position of the substituent (Figure 7A). Interestingly, 6-PN showed a different inhibitory effect than 8-PN 4–6 h after infection. In the influenza A virus, it has been reported that assembly of viral proteins and budding of mature virus particles take place in cells approximately 6–8 h after infection [44]. This suggests the possibility of inhibiting the growth process until viral maturation. DMEM containing bovine serum albumin (BSA) was used for the time-of-addition assay. From the results shown in Figure 5 and Figure 6, it is likely that part of the prenylated naringenin in the cells was bound to albumin in the medium. This binding may be involved in the intracellular and extracellular kinetics. Interactions between in vivo substances and flavonoids may affect the kinetics and anti-influenza virus efficacy. This experiment, in addition to Hanada’s report [25], indicates that prenylation of naringenin confers broad antiviral effects on influenza A and B viruses, broadening its potential as a novel antiviral agent. Moreover, in the process of chemical synthesis, diastereomeric mixtures of naringenin derivatives were generated and their separation was difficult due to their physical properties. Future research will focus on the effects of structure mixtures and subtle structural differences. However, this work is one of the few reports investigating the biological properties of flavonoid structures against influenza virus.
We were able to elucidate some of the structure-activity relationships of flavanone derivatives against influenza viruses, providing important information for antiviral strategies. Further study of this property may result in qualitative improvements in the pharmacological activity of drugs against influenza viruses.

4. Materials and Methods

4.1. General

All materials used for chemical synthesis not explicitly mentioned were purchased from Fujifilm Wako Pure Chemical Co. (Osaka, Japan), Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan), Nacalai Tesque, Inc. (Kyoto, Japan), and Sigma-Aldrich (St. Louis, MO, USA). (±)—Naringenin was purchased from Cayman Chemical Co., (Ann Arbor, MI, USA) and was used directly without purification. 1H NMR (500 MHz) and 13C NMR (125 MHz) spectra were recorded using a JEOL JNM-ECP500 spectrometer. Chemical shift values are expressed in ppm relative to the solvent residual signals of CDCl3 (7.26 ppm), DMSO-d6 (2.50 ppm) in 1H NMR, and CDCl3 (77.1 ppm), DMSO-d6 (39.5 ppm) in 13C NMR. TMS (tetramethylsilane) was used as an internal standard in case of using CDCl3. Abbreviations: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. The coupling constant values are expressed in hertz. High resolution mass spectrometry (HR-MS) was performed using an LTQ-Orbitrap XL Mass Spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) or LCMS-9030 mass spectrometer (Shimadzu, Kyoto, Japan). Melting points were measured using a Yanaco micro melting point apparatus, without correction. Flash column chromatography was performed using silica gel (Wakosil C-200; Fujifilm Wako Pure Chemical Co., Osaka, Japan). Analytical thin-layer chromatography was performed on Silica gel 60 F254 glass plates (Merck Millipore, Burlington, MA, USA) and visualized using a UV lamp. All compounds were dissolved in dimethyl sulfoxide and stored at −30 °C. The compounds were synthesized according to the literature [45,46,47,48,49,50] and supplemental materials.

4.2. Cell and Viruses

MDCK cells were grown in Eagle’s minimum essential medium (MEM; Fujifilm Wako Pure Chemical Co., Osaka, Japan) containing 7% FBS. Type A influenza virus H1N1 (PR/8/34) was used in the experiments. To infect the cells, the virus was diluted in serum-free MEM containing 0.04% BSA (fraction V; Sigma-Aldrich, St. Louis, MO, USA) and incubated with the cells at a multiplicity of infection of 0.001 for 1 h at 37 °C. The medium was then removed and replaced with serum-free DMEM containing 0.4% BSA and 2 µg/mL acetyl trypsin (Sigma-Aldrich, St. Louis, MO, USA) for the remainder of the infection period. For fluorescence microscopy, cells were grown in DMEM (Fujifilm Wako Pure Chemical Co., Osaka, Japan) without phenol red containing 1% FBS and 2 mM glutamine.
MDCK cells and the A/PR/8/34 strain were obtained from the Research Institute for Microbial Diseases (Osaka University, Suita, Osaka, Japan).

4.3. Cell Viability Determination

Cell viability was determined using the Cell Proliferation Kit I (MTT) (F. Hoffmann–La Roche Ltd., Basel, Switzerland). The cytopathic effect on the virus-infected cells treated with various concentrations of flavonoids was observed under a microscope. The experiment was performed at a concentration that was not cytotoxic.

4.4. Determination of Cell Viability in the Presence of Naringenin Derivatives

The effects of naringenin derivatives on viral yield were determined according to a previously described procedure [51,52]. The focus-forming reduction assay for viral activity was performed according to a previously described procedure [51,52].

4.5. Cellular Uptake of Naringenin and Its Derivatives

Fluorescence microscopy experiments were performed according to Wolff et al. [30]. Briefly, cells were plated in glass-bottom dishes (Matsunami, Osaka, Japan) and cultured in a medium without phenol red. Cells were exposed to 30 μM naringenin and its derivatives, and phase-contrast and fluorescence images were acquired for a fixed exposure time before and after the addition of the compounds at defined intervals. For the imaging, we prepared a custom-built filter (ex 470/40, em 605/70). Upon excitation at approximately 470 nm (bandwidth of 40 nm), a major emission was observed at approximately 605 nm (bandwidth of 70 nm). The emission signal from naringenin and its derivatives was detectable at wavelengths > 565 nm, making it possible to design filters that avoid cellular autofluorescence in the green range.
Fluorescence microscopy of living and fixed cells was performed using an inverted fluorescence phase-contrast microscope (Keyence BZ-X800), consisting of an infinity optical system (Nikon CFI60 series with software BZ-H4 series; Keyence, Osaka, Japan).

4.6. Estimation of Intracellular Naringenin and Prenylated Naringenin

Cells were cultured on glass plates and incubated in a medium supplemented with the compound for 180 min. They were then washed and fixed with 4% paraformaldehyde for 30 min. After washing with PBS, DAPI staining was performed. Intracellular distribution was photographed and observed using an inverted fluorescence phase-contrast microscope (BZ-X800, Keyence, Osaka, Japan).

4.7. Time-of-Addition Assay

We conducted a time-of-addition assay as previously described [51,52]. DMEM containing prenylated naringenin (30 μM) was added at −1–0 h (adsorption), 0–8 h (replication), 0–4 h, 0–2 h, 2–4 h, 4–8 h, 4–6 h, and 6–8 h. Furuta et al. [44] estimated the intracellular cycle of infected cells before extracellular budding to be 8 h, and growth stages were assumed to occur at 2 h intervals.

4.8. Statistical Analysis

Statistical analyses were performed using the unpaired t-test and analysis of variance with the Tukey–Kramer test using SPSS ver. 21.0 software (SPSS, Inc., Chicago, IL, USA). Statistical significance was set at p < 0.05.

5. Conclusions

Naringenin, a flavanone found mainly in vegetables and fruits, has been reported to possess various physiological functions, including antiviral activity. In this study, we investigated the relationship between the antiviral activity of naringenin, prenylated naringenin, and their derivatives against influenza infection as well as the cellular uptake of these flavanones. Our results indicated that the steric effect of the compounds is an important factor in their antiviral activity. In the structure of naringenin, the substituent that enhances antiviral activity is the prenyl group, and its structure and position have a significant effect on its cell permeability. We hope that the results of this study will be useful for the development of future therapeutic drugs against viruses.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15121480/s1. Figure S1. 1H NMR chart of compound 3; Figure S2. 1H NMR chart of compound 4; Figure S3. 1H NMR chart of compound 5; Figure S4. 1H NMR chart of compound 7; Figure S5. 1H NMR chart of compound 8-PN; Figure S6. 1H NMR chart of compound 1c; Figure S7. 13C NMR chart of compound 1c; Figure S8. ESI-HR-MS chart of compound 1c; Figure S9. 1H NMR chart of compound 1d; Figure S10. 13C NMR chart of compound 1d; Figure S11. ESI-HR-MS chart of compound 1d; Figure S12. 1H NMR chart of compound 8; Figure S13. 13C NMR chart of compound 8; Figure S14. ESI-HR-MS chart of compound 8; Figure S15. 1H NMR chart of compound 1a; Figure S16. 13C NMR chart of compound 1a; Figure S17. ESI-HR-MS chart of compound 1a; Figure S18. 1H NMR chart of compound 1b; Figure S19. 13C NMR chart of compound 1b; Figure S20. ESI-HR-MS chart of compound 1b; Figure S21. 1H NMR chart of compound 10; Figure S22. 13C NMR chart of compound 10; Figure S23. ESI-HR-MS chart of compound 10; Figure S24. 1H NMR chart of compound 1e; Figure S25. 13C NMR chart of compound 1e; Figure S26. ESI-HR-MS chart of compound 10; Figure S27. 1H NMR chart of compound 2a; Figure S28. 13C NMR chart of compound 2a; Figure S29. 1H NMR chart of compound 6-PN; Figure S30. 1H NMR chart of compound 12; Figure S31. 1H NMR chart of compound 2b; Figure S32. 1H NMR chart of compound 13; Figure S33. 13C NMR chart of compound 13; Figure S34. ESI-HR-MS chart of compound 13; Figure S35. 1H NMR chart of compound 2c; Figure S36. 13C NMR chart of compound 2c; Figure S37. ESI-HR-MS chart of compound 2c; Figure S38. 1H NMR chart of compound 14; Figure S39. 13C NMR chart of compound 14; Figure S40. HR-MS chart of compound 14; Figure S41. 1H NMR chart of compound 2d; Figure S42. 13C NMR chart of compound 2d; Figure S43. ESI-HR-MS chart of compound 2d. Refs. [53,54] are cited in supplementary materials

Author Contributions

Material preparation, R.M., C.M. and A.H.; data collection and analysis, R.M.; resources, Y.O. and T.O.; supervision, Y.I.; writing—original draft preparation, R.M.; writing—editing, Y.I. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Grant-in-Aid for Scientific Research (C) (Grant numbers 18K11117 and 22K11792) from the Japan Society for the Promotion of Science (KAKENHI).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Acknowledgments

We thank Yasuhiko Horiguchi of the Research Institute for Microbial Diseases, Osaka University, for the use of a fluorescence phase-contrast microscope (Keyence BZ-X800).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sawakami, T.; Karako, K.; Song, P. Behavioral changes adopted to constrain COVID-19 in Japan: What are the implications for seasonal influenza prevention and control? Glob. Health Med. 2021, 3, 125–128. [Google Scholar] [CrossRef] [PubMed]
  2. Zhang, A.J.; Lee, A.C.; Chan, J.F.; Liu, F.; Li, C.; Chen, Y.; Chu, H.; Lau, S.Y.; Wang, P.; Chan, C.C.; et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1) pdm09 virus enhances the severity of pneumonia in golden. Clin. Infect. Dis. 2021, 72, e978–e992. [Google Scholar] [CrossRef]
  3. Drake, T.; Ho, A.; Turtle, L.; Russell, C.; Harrison, E.; Semple, C. Influenza infection in patients hospitalized with COVID-19: Rapid Report from CO-CIN Data. In Proceedings of the 59 SAGE Meeting, London, UK, 24 September 2020. [Google Scholar]
  4. Honigsbaum, M. Revisiting the 1957 and 1968 influenza pandemics. Lancet 2020, 395, 1824–1826. [Google Scholar] [CrossRef] [PubMed]
  5. Elderfield, R.; Barclay, W. Influenza pandemics. Adv. Exp. Med. Biol. 2011, 719, 81–103. [Google Scholar] [CrossRef] [PubMed]
  6. Boonnak, K.; Mansanguan, C.; Schuerch, D.; Boonyuen, U.; Lerdsamran, H.; Jiamsomboon, K.; Sae Wong, F.; Huntrup, A.; Prasertsopon, J.; Kosoltanapiwat, N.; et al. Molecular characterization of seasonal influenza A and B from hospitalized patients in thailand in 2018–2019. Viruses 2021, 13, 977. [Google Scholar] [CrossRef]
  7. Kim, H.M.; Lee, N.; Kim, M.S.; Kang, C.; Chung, Y.S. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the republic of korea. Virol. J. 2020, 17, 94. [Google Scholar] [CrossRef] [PubMed]
  8. Hayden, F.G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M.D.; Hurt, A.C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; et al. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 2018, 379, 913–923. [Google Scholar] [CrossRef] [PubMed]
  9. Lampejo, T. Influenza and antiviral resistance: An overview. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 1201–1208. [Google Scholar] [CrossRef] [PubMed]
  10. Miles, E.A.; Calder, P.C. Effects of citrus fruit juices and their bioactive components on inflammation and immunity: A narrative review. Front. Immunol. 2021, 12, 712608. [Google Scholar] [CrossRef] [PubMed]
  11. Ali, M.Y.; Sina, A.A.; Khandker, S.S.; Neesa, L.; Tanvir, E.M.; Kabir, A.; Khalil, M.I.; Gan, S.H. Nutritional composition and bioactive compounds in tomatoes and their impact on human health and disease: A review. Foods 2020, 10, 45. [Google Scholar] [CrossRef] [PubMed]
  12. Santhi, V.P.; Masilamani, P.; Sriramavaratharajan, V.; Murugan, R.; Gurav, S.S.; Sarasu, V.P.; Parthiban, S.; Ayyanar, M. Therapeutic potential of phytoconstituents of edible fruits in combating emerging viral infections. J. Food Biochem. 2021, 45, e13851. [Google Scholar] [CrossRef] [PubMed]
  13. Hernández-Aquino, E.; Muriel, P. Beneficial effects of naringenin in liver diseases: Molecular mechanisms. World. J. Gastroenterol. 2018, 24, 1679–1707. [Google Scholar] [CrossRef]
  14. Chen, Z.; Chen, P.; Wu, H.; Shi, R.; Su, W.; Wang, Y.; Li, P. Evaluation of naringenin as a promising treatment option for COPD based on literature review and network pharmacology. Biomolecules 2020, 10, 1644. [Google Scholar] [CrossRef] [PubMed]
  15. Khan, A.; Ikram, M.; Hahm, J.R.; Kim, M.O. Antioxidant and anti-inflammatory effects of citrus flavonoid hesperetin: Special focus on neurological disorders. Antioxidants 2020, 9, 609. [Google Scholar] [CrossRef] [PubMed]
  16. Motallebi, M.; Bhia, M.; Rajani, H.F.; Bhia, I.; Tabarraei, H.; Mohammadkhani, N.; Pereira-Silva, M.; Kasaii, M.S.; Nouri-Majd, S.; Mueller, A.L.; et al. Naringenin: A potential flavonoid phytochemical for cancer therapy. Life Sci. 2022, 305, 120752. [Google Scholar] [CrossRef] [PubMed]
  17. Thayumanavan, G.; Jeyabalan, S.; Fuloria, S.; Sekar, M.; Ravi, M.; Selvaraj, L.K.; Bala, L.; Chidambaram, K.; Gan, S.H.; Rani, N.N.I.M.; et al. Silibinin and naringenin against bisphenol A-Induced neurotoxicity in zebrafish model-potential flavonoid molecules for new drug design, development, and therapy for neurological disorders. Molecules 2022, 27, 2572. [Google Scholar] [CrossRef]
  18. Salehi, B.; Fokou, P.V.T.; Sharifi-Rad, M.; Zucca, P.; Pezzani, R.; Martins, N.; Sharifi-Rad, J. The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals 2019, 12, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Montenegro-Landívar, M.F.; Tapia-Quirós, P.; Vecino, X.; Reig, M.; Valderrama, C.; Granados, M.; Cortina, J.L.; Saurina, J. Polyphenols and their potential role to fight viral diseases: An overview. Sci. Total Environ. 2021, 801, 149719. [Google Scholar] [CrossRef] [PubMed]
  20. Venturelli, S.; Niessner, H.; Sinnberg, T.; Berger, A.; Burkard, M.; Urmann, C.; Donaubauer, K.; Böcker, A.; Leischner, C.; Riepl, H.; et al. 6- and 8-prenylnaringenin, novel natural histone deacetylase inhibitors found in hops, exert antitumor activity on melanoma cells. Cell. Physiol. Biochem. 2018, 51, 543–556. [Google Scholar] [CrossRef]
  21. Liu, M.; Hansen, P.E.; Wang, G.; Qiu, L.; Dong, J.; Yin, H.; Qian, Z.; Yang, M.; Miao, J. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules 2015, 20, 754–779. [Google Scholar] [CrossRef] [PubMed]
  22. Štulíková, K.; Karabín, M.; Nešpor, J.; Dostálek, P. Therapeutic perspectives of 8-prenylnaringenin, a potent phytoestrogen from hops. Molecules 2018, 23, 660. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Mukai, R. Prenylation enhances the biological activity of dietary flavonoids by altering their bioavailability. Biosci. Biotechnol. Biochem. 2018, 82, 207–215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Grienke, U.; Richter, M.; Walther, E.; Hoffmann, A.; Kirchmair, J.; Makarov, V.; Nietzsche, S.; Schmidtke, M.; Rollinger, J.M. Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae. Sci. Rep. 2016, 6, 27156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Hanada, A.; Morimoto, R.; Horio, Y.; Shichiri, M.; Nakashima, A.; Ogawa, T.; Suzuki, K.; Sumitani, H.; Ogata, T.; Isegawa, Y. Influenza virus entry and replication inhibited by 8-prenylnaringenin from Citrullus lanatus var. citroides (wild watermelon). Food Sci. Nutr. 2022, 10, 926–935. [Google Scholar] [CrossRef]
  26. Seliger, J.M.; Misuri, L.; Maser, E.; Hintzpeter, J. The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10. J. Enzyme Inhib. Med. Chem. 2018, 33, 607–614. [Google Scholar] [CrossRef] [Green Version]
  27. Tronina, T.; Popłoński, J.; Bartmańska, A. Flavonoids as phytoestrogenic components of hops and beer. Molecules, 2020; 25, 4201. [Google Scholar] [CrossRef]
  28. Morimoto, R.; Hanada, A.; Matsubara, C.; Horio, Y.; Sumitani, H.; Ogata, T.; Isegawa, Y. Anti-influenza A virus activity of flavonoids in vitro: A structure-activity relationship. J. Nat. Med. 2022, in press. [Google Scholar] [CrossRef]
  29. Mukai, R.; Fujikura, Y.; Murota, K.; Uehara, M.; Minekawa, S.; Matsui, N.; Kawamura, T.; Nemoto, H.; Terao, J. Prenylation enhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J. Nutr. 2013, 143, 1558–1564. [Google Scholar] [CrossRef] [Green Version]
  30. Wolff, H.; Motyl, M.; Hellerbrand, C.; Heilmann, J.; Kraus, B. Xanthohumol uptake and intracellular kinetics in hepatocytes, hepatic stellate cells, and intestinal cells. J. Agric. Food Chem. 2011, 59, 12893–12901. [Google Scholar] [CrossRef]
  31. Liu, C.H.; Jassey, A.; Hsu, H.Y.; Lin, L.T. Antiviral activities of silymarin and derivatives. Molecules 2019, 24, 1552. [Google Scholar] [CrossRef]
  32. Di Petrillo, A.; Orrù, G.; Fais, A.; Fantini, M.C. Quercetin and its derivates as antiviral potentials: A comprehensive review. Phytother. Res. 2022, 36, 266–278. [Google Scholar] [CrossRef] [PubMed]
  33. Sadati, S.M.; Gheibi, N.; Ranjbar, S.; Hashemzadeh, M.S. Docking study of flavonoid derivatives as potent inhibitors of influenza H1N1 virus neuraminidase. Biomed. Rep. 2019, 10, 33–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Zima, V.; Radilová, K.; Kožíšek, M.; Albiñana, C.B.; Karlukova, E.; Brynda, J.; Fanfrlík, J.; Flieger, M.; Hodek, J.; Weber, J.; et al. Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. Eur. J. Med. Chem. 2020, 208, 112754. [Google Scholar] [CrossRef] [PubMed]
  35. Tian, Y.; Sang, H.; Liu, M.; Chen, F.; Huang, Y.; Li, L.; Liu, S.; Yang, J. Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation. Microbes. Infect. 2020, 22, 254–262. [Google Scholar] [CrossRef] [PubMed]
  36. Frabasile, S.; Koishi, A.C.; Kuczera, D.; Silveira, G.F.; Verri, W.A., Jr.; Duarte Dos Santos, C.N.; Bordignon, J. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci. Rep. 2017, 7, 41864. [Google Scholar] [CrossRef] [Green Version]
  37. Tutunchi, H.; Naeini, F.; Ostadrahimi, A.; Hosseinzadeh-Attar, M.J. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19. Phytother. Res. 2020, 34, 3138–3147. [Google Scholar] [CrossRef] [PubMed]
  38. Murota, K.; Shimizu, S.; Miyamoto, S.; Izumi, T.; Obata, A.; Kikuchi, M.; Terao, J. Unique uptake and transport of isoflavone aglycones by human intestinal caco-2 cells: Comparison of isoflavonoids and flavonoids. J. Nutr. 2002, 132, 1956–1961. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Tanaka, Y.; Okuyama, H.; Nishikawa, M.; Ikushiro, S.I.; Ikeda, M.; Ishima, Y.; Ukawa, Y.; Oe, K.; Teramo, J.; Mukai, R. 8-Prenylnaringenin tissue distribution and pharmacokinetics in mice and its binding to human serum albumin and cellular uptake in human embryonic kidney cells. Food Sci. Nutr. 2022, 10, 1070–1080. [Google Scholar] [CrossRef] [PubMed]
  40. De Simone, G.; di Masi, A.; Ascenzi, P. Serum albumin: A multifaced enzyme. Int. J. Mol. Sci. 2021, 22, 10086. [Google Scholar] [CrossRef] [PubMed]
  41. Bolli, A.; Marino, M.; Rimbach, G.; Fanali, G.; Fasano, M.; Ascenzi, P. Flavonoid binding to human serum albumin. Biochem. Biophys. Res. Commun. 2010, 398, 444–449. [Google Scholar] [CrossRef] [PubMed]
  42. Joyner, P.M. Protein adducts and protein oxidation as molecular mechanisms of flavonoid bioactivity. Molecules 2021, 26, 5102. [Google Scholar] [CrossRef] [PubMed]
  43. Mukai, R.; Shirai, Y.; Saito, N.; Yoshida, K.; Ashida, H. Subcellular localization of flavonol aglycone in hepatocytes visualized by confocal laser scanning fluorescence microscope. Cytotechnology 2009, 59, 177–182. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Furuta, Y.; Takahashi, K.; Kuno-Maekawa, M.; Sangawa, H.; Uehara, S.; Kozaki, k.; Nomura, N.; Egawa, H.; Shiraki, K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49, 981–986. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Gester, S.; Metz, P.; Zierau, O.; Vollmer, G. An efficient synthesis of the potent phytoestrogens 8-prenylnaringenin and 6-(1,1-Dimethylallyl) naringenin by europium (III)-catalyzed claisen rearrangement. Tetrahedron 2001, 57, 1015–1018. [Google Scholar] [CrossRef]
  46. Tischer, S.; Metz, P. Selective C-6 prenylation of flavonoids via europiumA (III)-catalyzed claisen rearrangement and cross-metathesis. Adv. Synth. Catal. 2007, 349, 147–151. [Google Scholar] [CrossRef]
  47. Ogata, T.; Tanaka, M.; Ishigaki, M.; Shimizu, M.; Nishiuchi, A.; Inamoto, K.; Kimachi, T. The first enantioselective total synthesis of lantalucratin C and determination of its absolute configuration. Tetrahedron 2015, 71, 6672–6680. [Google Scholar] [CrossRef]
  48. Su, W.; Wang, Y. PCT Int. Appl. WO 2014094370 A1 20140626. 2014. Available online: https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2014094370&_cid=JP2-LAW15C-87721-1 (accessed on 5 October 2022).
  49. Laettig, J.; Boehl, M.; Fischer, P.; Tischer, S.; Tietboehl, C.; Menschikowski, M.; Gutzeit, H.O.; Metz, P.; Pisabarro, M.T.; Comput, J. Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: Rationale for lead design. J. Comput. Aided Mol. Des. 2007, 21, 473–483. [Google Scholar] [CrossRef] [PubMed]
  50. Du Nguyen, H.; Okada, T.; Kitamura, S.; Yamaoka, S.; Horaguchi, Y.; Kasanami, Y.; Sekiguchi, F.; Tsubota, M.; Yoshida, S.; Nishikawa, H.; et al. Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. Bioorg. Med. Chem. 2018, 26, 4410–4427. [Google Scholar] [CrossRef] [PubMed]
  51. Morimoto, R.; Yoshioka, K.; Nakayama, M.; Nagai, E.; Okuno, Y.; Nakashima, A.; Ogawa, T.; Suzuki, K.; Enomoto, T.; Isegawa, Y. Juice of citrullus lanatus var. citroides (wild watermelon) inhibits the entry and propagation of influenza viruses in vitro and in vivo. Food Sci. Nutr. 2021, 9, 544–552. [Google Scholar] [CrossRef]
  52. Nagai, E.; Iwai, M.; Koketsu, R.; Sogabe, R.; Morimoto, R.; Suzuki, Y.; Ohta, Y.; Okuno, Y.; Ohshima, A.; Enomoto, T.; et al. Inhibition of influenza virus replication by adlay tea. J. Sci. Food Agric. 2018, 98, 1899–1905. [Google Scholar] [CrossRef] [PubMed]
  53. Hänsel, R.; Schulz, J. Desmethylxanthohumol: Isolierung aus hopfen und cyclisierung zu flavanonen. Arch. Pharm. 1988, 321, 37–40. [Google Scholar]
  54. Kumano, T.; Richard, S.B.; Noel, J.P.; Nishiyama, M.; Kuzuyama, T. Chemoenzymatic synthesis of prenylated aromatic small molecules using streptomyces prenyltransferases with relaxed substrate specificities. Bioorg. Med. Chem. 2008, 16, 8117–8126. [Google Scholar]
Pharmaceuticals 15 01480 g001 550
Figure 1. Time course and fluorescence images of prenylated naringenin and other derivatives. (A) Fluorescence intensity of 8-PN, 6-PN, naringenin, and naringenin-4′,7′-diacetate. (B) Fluorescence images.
Figure 1. Time course and fluorescence images of prenylated naringenin and other derivatives. (A) Fluorescence intensity of 8-PN, 6-PN, naringenin, and naringenin-4′,7′-diacetate. (B) Fluorescence images.
Pharmaceuticals 15 01480 g001
Pharmaceuticals 15 01480 g002 550
Figure 2. Time course and fluorescence images of 8-position naringenin derivatives. (A) Fluorescence intensity of 8-position naringenin derivatives. (B) Fluorescence images.
Figure 2. Time course and fluorescence images of 8-position naringenin derivatives. (A) Fluorescence intensity of 8-position naringenin derivatives. (B) Fluorescence images.
Pharmaceuticals 15 01480 g002
Pharmaceuticals 15 01480 g003 550
Figure 3. Time course and fluorescence images of 6-position naringenin derivatives. (A) Fluorescence intensity of 6-position naringenin derivatives. (B) Fluorescence images. Madin–Darby canine kidney (MDCK) cells were treated with 30 μM of the compound in phenol red-free medium. We measured the mean fluorescence intensity at each time point (60, 120, 180, and 360 min), which was calculated from approximately 20 cells per time point. (B) Images show cells after 180 min of compound treatment. Scale bars = 50 μm.
Figure 3. Time course and fluorescence images of 6-position naringenin derivatives. (A) Fluorescence intensity of 6-position naringenin derivatives. (B) Fluorescence images. Madin–Darby canine kidney (MDCK) cells were treated with 30 μM of the compound in phenol red-free medium. We measured the mean fluorescence intensity at each time point (60, 120, 180, and 360 min), which was calculated from approximately 20 cells per time point. (B) Images show cells after 180 min of compound treatment. Scale bars = 50 μm.
Pharmaceuticals 15 01480 g003
Pharmaceuticals 15 01480 g004 550
Figure 4. Analysis of prenylated naringenin and naringenin fluorescence distribution by imaging. After removing the medium, cells were treated with 30 μM compound for 180 min and fixed with 4% paraformaldehyde. Fixed cells were stained with DAPI (blue). These images show fluorescence of 8-prenylnaringenin (8-PN; A), 6-prenylnaringenin (6-PN; B), and naringenin (C). Scale bars = 50 μm.
Figure 4. Analysis of prenylated naringenin and naringenin fluorescence distribution by imaging. After removing the medium, cells were treated with 30 μM compound for 180 min and fixed with 4% paraformaldehyde. Fixed cells were stained with DAPI (blue). These images show fluorescence of 8-prenylnaringenin (8-PN; A), 6-prenylnaringenin (6-PN; B), and naringenin (C). Scale bars = 50 μm.
Pharmaceuticals 15 01480 g004
Pharmaceuticals 15 01480 g005 550
Figure 5. Efflux of prenylated naringenin after intracellular saturation. The amount of the compound in the cells was saturated by exposure for 180 min, and the cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) for 0, 120, and 240 min. After removing the medium, cells were fixed with 4% paraformaldehyde and stained with DAPI (blue). These images show 8-PN (A) and 6-PN (B) fluorescence. Scale bars = 50 μm.
Figure 5. Efflux of prenylated naringenin after intracellular saturation. The amount of the compound in the cells was saturated by exposure for 180 min, and the cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) for 0, 120, and 240 min. After removing the medium, cells were fixed with 4% paraformaldehyde and stained with DAPI (blue). These images show 8-PN (A) and 6-PN (B) fluorescence. Scale bars = 50 μm.
Pharmaceuticals 15 01480 g005
Pharmaceuticals 15 01480 g006 550
Figure 6. Efflux and fluorescence intensity of intracellular prenylated naringenins. Fluorescence intensity of 8-PN and 6-PN from Figure 5. The standard deviation bars are indicated on each bar graph. *** p < 0.001.
Figure 6. Efflux and fluorescence intensity of intracellular prenylated naringenins. Fluorescence intensity of 8-PN and 6-PN from Figure 5. The standard deviation bars are indicated on each bar graph. *** p < 0.001.
Pharmaceuticals 15 01480 g006
Pharmaceuticals 15 01480 g007 550
Figure 7. Effect of prenylated naringenin on virus viability. (A) 8-PN and 6-PN (30 μM). (B) Schedule of the experiment. Cells were infected with influenza virus A/PR/8/34 at a multiplicity of infection of 0.01 in 24-well plates. After infection at each time point, the cells were harvested and viruses were assayed using a focus-forming reduction assay. Each column shows virus viability at each stage of virus growth induced by 8-PN and 6-PN. Data are representative of three independent experiments. Standard deviation bars indicate each bar graph (*** p < 0.001, ** p < 0.01).
Figure 7. Effect of prenylated naringenin on virus viability. (A) 8-PN and 6-PN (30 μM). (B) Schedule of the experiment. Cells were infected with influenza virus A/PR/8/34 at a multiplicity of infection of 0.01 in 24-well plates. After infection at each time point, the cells were harvested and viruses were assayed using a focus-forming reduction assay. Each column shows virus viability at each stage of virus growth induced by 8-PN and 6-PN. Data are representative of three independent experiments. Standard deviation bars indicate each bar graph (*** p < 0.001, ** p < 0.01).
Pharmaceuticals 15 01480 g007
Table
Table 1. Anti-viral effects of prenylated naringenin and derivatives.
Table 1. Anti-viral effects of prenylated naringenin and derivatives.
Compound NameStructureIC50 a (μM)SI b
(±)-Naringenin (Na)Pharmaceuticals 15 01480 i001290 ± 16.24.9
Naringenin-4′,7′-diacetate (Na-di)Pharmaceuticals 15 01480 i002NDND
8-prenylnaringenin (8-PN)Pharmaceuticals 15 01480 i00324 ± 0.64.9
6-prenylnaringenin (6-PN)Pharmaceuticals 15 01480 i00438 ± 4.75.5
1aPharmaceuticals 15 01480 i00559 ± 9.02.7
1bPharmaceuticals 15 01480 i006NDND
1ePharmaceuticals 15 01480 i007NDND
1cPharmaceuticals 15 01480 i00842 ± 2.16.3
1dPharmaceuticals 15 01480 i00961 ± 14.03.0
2aPharmaceuticals 15 01480 i010103 ± 3.80.8
2bPharmaceuticals 15 01480 i01158 ± 15.21.3
2cPharmaceuticals 15 01480 i012NDND
2dPharmaceuticals 15 01480 i013NDND
a Values are the average of the results obtained using various final concentration of compounds and MDCK cells from three independent experiments. The IC50 of compounds were reported as μM. The values after ‘‘±’’ in the IC50 are the standard deviations. The IC50 value for oseltamivir acid in the A/PR/8/34 strain was 2.0 ± 0.7 nM. b Selectivity index = CC50/IC50(CC50, 50% cytotoxicity concentration; IC50, 50% maximal inhibitory concentration); ND: Not detected.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Morimoto, R.; Matsubara, C.; Hanada, A.; Omoe, Y.; Ogata, T.; Isegawa, Y. Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones. Pharmaceuticals 2022, 15, 1480. https://doi.org/10.3390/ph15121480

AMA Style

Morimoto R, Matsubara C, Hanada A, Omoe Y, Ogata T, Isegawa Y. Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones. Pharmaceuticals. 2022; 15(12):1480. https://doi.org/10.3390/ph15121480

Chicago/Turabian Style

Morimoto, Ryosuke, Chiaki Matsubara, Akari Hanada, Yuta Omoe, Tokutaro Ogata, and Yuji Isegawa. 2022. "Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones" Pharmaceuticals 15, no. 12: 1480. https://doi.org/10.3390/ph15121480

APA Style

Morimoto, R., Matsubara, C., Hanada, A., Omoe, Y., Ogata, T., & Isegawa, Y. (2022). Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones. Pharmaceuticals, 15(12), 1480. https://doi.org/10.3390/ph15121480

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop